Percutaneous Coronary Intervention Market Research Report Information by Product Type (Coronary Stents, Balloon Catheters, Coronary Guidewires, Guiding Catheters, Guiding Sheaths, Diagnostics Catheters, Crossing Catheters, Inflation Devices, Guidance Systems, Peripheral Thrombectomy System, Embolic Protection System, And Accessories), by Vascular Access (Radial and Femoral), by End User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and by Region (North America, Europe, Asia-Pacific, and Rest of the World - Forecast till 20

Global Percutaneous Coronary Intervention Market Overview

The Percutaneous Coronary Intervention Market size was valued at USD 8.78 Billion in 2023 and is projected to grow from USD 9.55 Billion in 2024 to USD 20.53 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.03% during the forecast period (2024 - 2032).

“The percutaneous coronary intervention market is set for robust growth driven by technological advancements, increasing prevalence of cardiovascular diseases, and a rising aging population. With a focus on minimally invasive procedures and innovative stent technologies, the market is poised to witness sustained expansion, offering improved patient outcomes, and contributing to the evolution of interventional cardiology.”

The expected growth in the market can be attributed to the rising prevalence of heart diseases and increasing preference for minimally invasive procedures.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Percutaneous Coronary Intervention Trends

• Rising prevalence of heart diseases fuels market growth

Over the last 30 years, the number of death and disabilities caused by cardiovascular disease has continuously increased around the world. The disorder, which includes heart disease and stroke, was responsible for one-third of the deaths across the globe in 2019. For instance, in 2019, the World Health Organiation estimated that nearly 17.9 million individuals died from cardiovascular diseases, accounting for 32% of all global fatalities. Heart attacks and strokes were responsible for 85% of these fatalities. Unhealthy food, physical inactivity, cigarette use, and problematic alcohol consumption are the most major behavioural risk factors for heart disease and stroke. Individuals may experience elevated blood pressure, elevated blood glucose, elevated blood lipids, and overweight or obesity because of behavioural risk factors. These "intermediate risks factors" may be assessed in primary care settings and suggest an elevated risk of heart attack, stroke, heart failure, and other consequences. The individuals that undergo surgery due to heart diseases are also growing. Therefore, due to the rising prevalence of heart diseases the market for global percutaneous coronary intervention will grow at a positive pace.

Percutaneous Coronary Intervention Segment Insights

Percutaneous Coronary Intervention Product Type Insights

The Percutaneous Coronary Intervention Market segmentation, based on product type, includes coronary stents, ballon catheters, coronary guidewires, guiding catheters, guiding sheaths, diagnostic catheters, crossing catheters, inflation device, guidance system, peripheral thrombectomy system, embolic protection system, and accessories. The coronary stents segment held the majority share in the market in 2022. Moreover, the launch of the newest generation of drug-eluting catheter stents to fulfill the demand of physicians is fueling the growth of the product type segment.

Percutaneous Coronary Intervention Vascular Access Insights

The Percutaneous Coronary Intervention Market segmentation, based on vascular access, includes radial and femoral. The radial segment dominated the market in 2022. Radial PCI is a safe and effective procedure that can be used to treat a variety of coronary artery diseases. It is the preferred approach to PCI for most patients because it offers several advantages over femoral PCI. Moreover, radial PCI is becoming increasingly popular due to advantages such as reducing the risk of stroke during the procedure and shortening the duration of the hospital stay.

Figure 2: Percutaneous Coronary Intervention Market, by Vascular Access, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Percutaneous Coronary Intervention End User Insights

The Percutaneous Coronary Intervention Market segmentation, based on end user, includes hospitals & clinics, ambulatory surgical centers, and others. The hospitals & clinics segment dominated the market in 2022. This is due to factors such as the increasing number of angioplasties, rising incidences of diabetes & obesity patients may lead to coronary artery diseases.

Percutaneous Coronary Intervention Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. The North America percutaneous coronary intervention market accounted for the largest market share in 2022. North America is further divided into the US and Canada. North America held the largest market share due to the increase in demand for minimally invasive procedures, increasing prevalence of cardiovascular diseases, and unhealthy lifestyle habits propelling regional market growth over the forecast period. For instance, In the United States, heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups. Cardiovascular disease claims one life every 33 seconds in the US. In 2021, approximately 695,000 people in the United States died from heart disease, accounting for one in every five deaths.

Further, the major countries will be study are US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: PERCUTANEOUS CORONARY INTERVENTION MARKET BY REGION 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe percutaneous coronary intervention market accounted for the second-largest market share due to unhealthy lifestyle habits, increasing geriatric population, and extensive R&D activities. Furthermore, the Germany percutaneous coronary intervention market is attributed to hold the largest market share, and the France percutaneous coronary intervention market is projected be the fastest growing market in the Europe region.

The Asia-Pacific percutaneous coronary intervention market is expected to be the fastest growing from 2023 to 2032 due to rising income levels, an increase in the prevalence of cardiovascular diseases, and better healthcare infrastructure. Moreover, China percutaneous coronary intervention market accounted to hold the largest market share, and the India percutaneous coronary intervention market is projected to be the fastest growing market in the Asia-Pacific region.

Percutaneous Coronary Intervention Key Market Players & Competitive Insights

The Percutaneous Coronary Intervention Market is distinguished by the presence of many global, regional, and local players. The rising prevalence of heart diseases and increasing preference for minimally invasive procedures are further expected to drive the growth of the Percutaneous Coronary Intervention Market during the forecast period. However, the risk of infection and complications during cardiac catheterization may hamper the growth of the Percutaneous Coronary Intervention Market. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their devices and signing contracts and agreements to broaden their reach and reduce operational costs. For instance, in April 2022, Boston Scientific Corporation (US) launched the Kinetix Guidewire for percutaneous coronary intervention (PCI) procedures. Guidewires are tiny, flexible wires that surgeons use to administer interventional devices like drug-eluting stents.

Boston Scientific Corporation is a well-established medical device company that is involved in the development, manufacture, and marketing of medical devices used in various interventional medical specialties. The company cooperates with healthcare professionals to create a broad portfolio of significant innovations that increase outcomes, reduce costs, and increase efficiencies. Its product portfolio is divided into interventional cardiology, endoscopy, neuromodulation, peripheral interventions, rhythm management, and urology & pelvic health. Boston Scientific Corporation's manufacturing facilities are positioned across Malaysia, the US, and Ireland. The company distributes its products in 130 countries across the world. Apart from this, it has a presence in Japan, the Netherlands, France, Poland, India, China, Turkey, South Africa, and Singapore, among others.

Moreover, In April 2022, Boston Scientific Corporation launched the Kinetix Guidewire for percutaneous coronary intervention (PCI) procedures. Guidewires are tiny, flexible wires that surgeons use to administer interventional devices like drug-eluting stents.

Key Companies in the Percutaneous Coronary Intervention market includes.

• Boston Scientific Corporation (US)


• Abbott (US)


• MicroPort Scientific Corporation (China)


• Terumo Corporation (Japan)


• Medtronic (Ireland)


• Cook (US)


• APT Medical Inc (China)


• Merit Medical System (US)


• Becton, Dickinson, and Company (US)


• Braun SE (Germany)


• Cardinal Health (US)


• Meril Life Sciences Pvt. Ltd (India)


• PLS Minimally Invasive International Medical Co Ltd (China)


• Lepu Medical Technology Co., Ltd (China)

Percutaneous Coronary Intervention Industry Developments

• In January 2023, MicroPort Scientific Corporation (China) received marketing approval for “MicroPort Coronary Balloon Catheters” in Peru. By this product approval company expand its business in Peru and support.


• In August 2022, Medtronic (Ireland) launched the Onyx Frontier drug-eluting stent (DES) System. The Onyx Frontier DES offers a unique delivery mechanism, built upon the acute performance and clinical data of the Resolute Onyx drug-eluting stent.


• In March 2022, MicroPort Scientific Corporation (China) received marketing approval from approval from Japan Pharmaceuticals and Medical Devices Agency (PMDA) for its product “Hyperflex”. The company can market its products in Japan and boost the revenue growth.

Percutaneous Coronary Intervention Segmentation

Percutaneous Coronary Intervention Product Type Outlook

• Coronary Stents


• Ballon Catheters
  
  
  
  • PCTA Balloon Catheters
  
  
  • Non-Slip Element & Scoring Balloon Catheters
  
  
  • Over-The-Wire Balloon Dilation Catheter
  
  
  • Fixed Wire Balloon Catheter
  
  
  • Drug Coated Balloon Catheters
  
  
  • Others
  
  
  
  


• Coronary Guidewires


• Guiding Catheters


• Guiding Sheaths


• Diagnostic Catheters


• Crossing Catheters


• Inflation Device


• Guidance System


• Peripheral Thrombectomy System


• Embolic Protection System


• Accessories

Percutaneous Coronary Intervention Vascular Access Outlook

• Radial


• Femoral

Percutaneous Coronary Intervention End User Outlook

• Hospitals & Clinics


• Ambulatory Surgical Centers


• Others

Percutaneous Coronary Intervention Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America